story of the week
Ocrelizumab Exposure in Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
J Neurol 2023 Oct 31;[EPub Ahead of Print], L Kappos, A Traboulsee, DKB Li, A Bar-Or, F Barkhof, X Montalban, D Leppert, A Baldinotti, HM Schneble, H Koendgen, A Sauter, Q Wang, SL HauserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.